Eco Animal Health Group plc announced the appointment of Dr Andrew Winder as Head of Business Development, effective from May 11, 2026. Andrew brings extensive strategic business development expertise to ECO, with a proven track record of driving profitable growth across global animal health markets. Andrew most recently served as Strategic Business Development Lead at Norbrook Laboratories Ltd. (Norbrook), a global provider of veterinary pharmaceuticals.
During his 14-year tenure at Norbrook, Andrew secured multiple co-development and distribution agreements, created a new global portfolio strategy that doubled the number of projects in Norbrook's pipeline, and negotiated distribution agreements with leading multi-national partners including Boehringer Ingelheim, Zoetis and Elanco. In his new role, Andrew will be responsible for identifying and securing strategic opportunities, including in-licensing partnerships to grow the Company's R&D pipeline. His appointment comes at a pivotal time as ECO progresses the EU commercial launch of its live vaccine for poultry, ECOVAXXIN MS, and continues to expand its position as a comprehensive solutions provider in animal health.
Andrew holds a PhD in Pharmaceutical Sciences from the University of Ulster and a BSc (Hons) in Microbiology from Queens University Belfast. He has also served as a member of the Board of Directors for Animal Health Europe.
